Ascletis Pharma Inc.
HKEX:1672.HK
1.51 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|
Assets: | ||||||||
Current Assets: | ||||||||
Cash & Cash Equivalents
| 330.117 | 2,470.834 | 2,495.496 | 2,714.011 | 2,989.164 | 3,173.249 | 607.367 | 418.973 |
Short Term Investments
| 1,969.286 | 11.2 | 5.2 | 2.209 | 4.788 | 1.664 | 143.831 | 5.61 |
Cash and Short Term Investments
| 2,303.246 | 2,482.034 | 2,500.696 | 2,714.011 | 2,989.164 | 3,173.249 | 751.198 | 424.583 |
Net Receivables
| 5.432 | 23.873 | 53.606 | 26.62 | 69.525 | 57.623 | 0 | 0 |
Inventory
| 6.071 | 20.519 | 56.233 | 58.894 | 86.039 | 83.877 | 62.211 | 18.747 |
Other Current Assets
| 19.434 | 15.652 | 18.423 | 28.253 | 43.058 | 46.923 | 58.131 | 22.678 |
Total Current Assets
| 2,332.756 | 2,544.726 | 2,631.551 | 2,829.987 | 3,192.574 | 3,363.336 | 875.618 | 466.008 |
Non-Current Assets: | ||||||||
Property, Plant & Equipment, Net
| 68.277 | 73.041 | 77.921 | 84.579 | 98.727 | 88.59 | 79.119 | 49.825 |
Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets
| 26.315 | 16.559 | 78.213 | 90.702 | 75.614 | 75.402 | 36.517 | 20.432 |
Goodwill and Intangible Assets
| 26.315 | 16.559 | 78.213 | 90.702 | 75.614 | 75.402 | 36.517 | 20.432 |
Long Term Investments
| -1,906.262 | 10.818 | 36.658 | 60.915 | 58.109 | 0 | 0 | 0 |
Tax Assets
| 1,969.286 | -10.818 | 0 | -60.915 | -58.109 | 0 | 0 | 0 |
Other Non-Current Assets
| 1,969.923 | 22.716 | 5.616 | 61.804 | 59.472 | 0.275 | 0 | 0 |
Total Non-Current Assets
| 158.253 | 112.316 | 198.408 | 237.085 | 233.813 | 164.267 | 115.636 | 70.257 |
Total Assets
| 2,491.009 | 2,657.042 | 2,829.959 | 3,067.072 | 3,426.387 | 3,527.603 | 991.254 | 536.265 |
Liabilities & Equity: | ||||||||
Current Liabilities: | ||||||||
Account Payables
| 0.649 | 3.135 | 1.054 | 0.93 | 6.643 | 14.191 | 12.967 | 0 |
Short Term Debt
| 5.71 | 2.416 | 1.568 | 1.144 | 2.226 | 0 | 0 | 0 |
Tax Payables
| 1.722 | 1.553 | 3.959 | 0.659 | 1.617 | 0.371 | 0.001 | 0.285 |
Deferred Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities
| 132.598 | 101.085 | 84.39 | 71.039 | 77.166 | 78.843 | 86.26 | 73.114 |
Total Current Liabilities
| 140.679 | 108.189 | 90.971 | 73.772 | 87.652 | 93.405 | 99.228 | 73.399 |
Non-Current Liabilities: | ||||||||
Long Term Debt
| 2.706 | 1.821 | 1.182 | 0.443 | 1.587 | 0 | 0 | 0 |
Deferred Revenue Non-Current
| 5.558 | 7.146 | 8.734 | 11.207 | 12.931 | 6.786 | 22.07 | 53.782 |
Deferred Tax Liabilities Non-Current
| 0 | -7.146 | -8.734 | -11.207 | -12.931 | 0 | 0.125 | 0 |
Other Non-Current Liabilities
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Liabilities
| 8.264 | 8.967 | 9.916 | 11.65 | 14.518 | 6.786 | 22.195 | 53.782 |
Total Liabilities
| 148.943 | 117.156 | 100.887 | 85.422 | 102.17 | 100.191 | 121.423 | 127.181 |
Equity: | ||||||||
Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 210.618 | 145.545 | 91.61 |
Common Stock
| 0.731 | 0.742 | 0.746 | 0.75 | 0.754 | 0.764 | 0.009 | 0.009 |
Retained Earnings
| -1,174.403 | -1,029.688 | -714.845 | -515.828 | -306.587 | -210.618 | -145.545 | -91.61 |
Accumulated Other Comprehensive Income/Loss
| 724.556 | 702.001 | 578.322 | 603.194 | 716.919 | -8.632 | -3.056 | -0.981 |
Other Total Stockholders Equity
| 2,791.182 | 2,866.831 | 2,864.849 | 2,893.534 | 2,913.131 | 2,538.154 | -53.311 | 0.624 |
Total Shareholders Equity
| 2,342.066 | 2,539.886 | 2,729.072 | 2,981.65 | 3,324.217 | 3,427.412 | 596.961 | 272.359 |
Total Equity
| 2,342.066 | 2,539.886 | 2,729.072 | 2,981.65 | 3,324.217 | 3,427.412 | 869.831 | 409.084 |
Total Liabilities & Shareholders Equity
| 2,491.009 | 2,657.042 | 2,829.959 | 3,067.072 | 3,426.387 | 3,527.603 | 991.254 | 536.265 |